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Abstract
It has been debated whether the Global Fund (GF), which is supporting the implementation of programs on the 
prevention and control of HIV/AIDS, tuberculosis (TB) and malaria, should consider the value-for-money (VFM) for 
programs/interventions that they are supporting. In this paper, we critically analyze the uses of economic information 
for GF programs, not only to ensure accountability to their donors but also to support country governments in 
continuing investment in cost-effective interventions initiated by the GF despite the discontinuation of financial 
support after graduation. We demonstrate that VFM is not a static property of interventions and may depend on 
program start-up cost, economies of scales, the improvement of effectiveness and efficiency of providers once the 
program develops, and acceptance and adherence of the target population. Interventions that are cost-ineffective 
in the beginning may become cost-effective in later stages. We consider recent GF commitments towards value for 
money and recommend that the GF supports interventions with proven cost-effectiveness from program initiation as 
well as interventions that may be cost-effective afterwards. Thus, the GF and country governments should establish 
mechanisms to monitor cost-effectiveness of interventions invested over time. 
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Introduction
The Global Fund (GF) is one of the biggest worldwide health 
development initiatives focusing on bringing the end of HIV/
AIDS, tuberculosis (TB), and malaria. Since its establishment 
in 2002, the Fund has relied on financial contributions 
from both public and private sectors.1 In 2015, the GF had 
received in total US$33 billion in cumulative and fully paid 
contributions. A pledging conference, during which donors 
and funders commit to assist the goals of the GF, was held 
in 2016. This is a timely paper that addresses a long debate 
in global communities on whether the GF, which implements 
vertical programs in three major diseases, should consider 
the value-for-money (VFM) of their investments on which 
level of governance and how this can be operationalized. The 
case study of Thailand is presented given the authors first-
hand experience in Thailand. Moreover, Thailand is now 
graduating from GF support and there are discussions on the 
sustainability of the GF investment. The authors reviewed 
relevant documents, both published and grey literature, 
as well as using direct experience of conducting health 
technology assessments (HTAs)[1] and health system and 
policy research to support decision-making in Thailand. We 
conclude by proposing a conceptual framework that can be 
used to guide the GF and country recipients in incorporating 
VFM information for implementing and monitoring the 
GF programs even well after graduation or transition from 
support. 
Thailand and the Global Fund
Thailand is an upper-middle income country with a 
population of 67 million and an average income per capita 
of $5561 in 2014.2 Since 2002, Thais have enjoyed universal 
health coverage (UHC) funded through public sources. 
Seventy-five percent of the total health expenditure in the 
country, amounting to 513 billion baht or equivalent to $16 
billion, is government funded.3 Although Thailand is facing 
the burden of non-communicable diseases (NCDs) due to 
its aging society, it still has challenges to overcome, namely 
communicable diseases, especially HIV/AIDS, TB, and 
malaria. HIV dropped from the top disease burden among 
Thais in 1999 with 1.3 million disability-adjusted life years 
(DALYs) lost, to the fifth place in 2009 with 0.44 million 
DALYs lost. On the other hand, TB is the 17th, with DALYs 
lost dropping from 0.16 in 1999 to 0.14 million in 2009. 
Malaria is not a common disease for most Thai communities, 
except in the border areas. The estimated burden of malaria in 
2009 is 0.003 million DALYs lost and is ranked 67th in terms 
of disease burden.4 The UHC benefit package has included 
TB and malaria treatments since its inception, whereas 
antiretroviral treatment for HIV was only included in 2005 
after the scaling up of treatment efforts from 2002.5 The 
spending for HIV/AIDS accounted for 2.4% of total health 
expenditure in Thailand or at approximately $330 million in 
2011, of which around 80% come from public funding and 
20% from others, predominantly the GF.6 For TB, the total 
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expenditure is approximately $30 million annually, with the 
government spending around $20 million. For malaria, the 
total spending is $9 million, which is mostly from the GF, 
with the government spending less than $1 million on efforts 
for the disease.7
As the only major overseas development partner who 
is funding healthcare in Thailand, the GF cumulatively 
contributed $540 million of grants for prevention and control 
of HIV/AIDS, TB and malaria since 2003. Because Thailand’s 
economy is consistently growing, the country is graduating 
from GF support in 2016 for HIV and TB and in 2017 for 
malaria. Although the percentage of financial support for 
HIV and TB from GF is relatively small compared to the 
budget (less than 10%) that the Thai government currently 
invests for the national HIV and TB programs,8 the target 
organizations for the GF grants are typically different from 
those which receive government investment. GF grants target 
non-state actors (NSAs) and/or community organizations to 
provide outreach services to populations that are overlooked 
by or are difficult to reach for the government programs. This 
is also due to the illegal status of most at-risk populations such 
as injecting drug users (IDU), female sex workers (FSW), 
and migrant workers. The formal Thai healthcare sector 
provides a primarily supportive role for NSAs to assist the 
GF program for HIV and TB, such as trainings or laboratory 
support. Because of its emphasis on high priority diseases and 
conditions by disease burden, UHC may disregard important 
disease burdens in small populations. However, UHC also 
focuses on infectious diseases that may begin with minority 
populations which is justifiable to minimize the possibility 
of epidemic outbreaks. For malaria, both the informal and 
formal sectors under various NSAs and the government 
benefit from the GF grant. The GF grant has been used for 
training of health professionals and finding cases in formal 
sectors; meanwhile, the informal sector receives the grant for 
communication and engagement in broader areas.
Thailand is considered a role model for having achieved UHC 
for its constituents as well as using evidence and HTA[1] to 
inform its health benefit package for medicines, vaccines, 
and non-pharmacological interventions.9-12 Despite this, 
HTA has rarely been used to inform decisions made by 
Thailand’s Country Coordinating Mechanism (CCM). The 
CCM consists of multiple stakeholders representing local 
partners and acts as a governing body of GF programs in the 
country. Its status as a separate entity may have prevented the 
integration of the benefits package development mechanism 
into the CCM’s processes. 
The Value-for Money of Global Fund Programs: A Silver 
Lining 
In 2012, the Thai CCM requested the Health Intervention 
and Technology Assessment Program (HITAP)[2] to conduct 
a mid-term review and evaluate the VFM of the GF’s program 
for HIV prevention targeting most-at-risk populations, 
namely, men that have sex with men (MSM), IDU, FSW, 
and migrant workers.13 While HTA[1] within the Thai health 
system has not been used specifically for infectious diseases 
within the population as a whole, its methods can still be 
used to understand the VFM of interventions for a targeted 
population. The results showed that the cost per infection 
averted is high and beyond the ceiling threshold (which at 
the time was 120 000 Thai baht per healthy life year gained), 
with the lowest cost for the IDU program at approximately 
300 000 baht per HIV case averted and the highest for the 
MSM program at 11 million baht per case averted[3]. Three 
factors can explain the inefficiency of this program: firstly, 
targeting hard-to-reach marginal groups resulted in a higher 
cost; secondly, the focus on assisting non-formal health sector 
and community organizations, both of which do not have 
adequate infrastructure, in providing the services required 
significant capital investment and human resource training; 
and, thirdly, the program, having been implemented for only 
2 years at the time of evaluation, had not yet reached its full 
potential due perhaps to lack of awareness and trust amongst 
the client or target population.
These three factors and the resulting inefficiency may 
be common in settings other than Thailand given that 
CCM managed GF programs separately from the country 
government; however, this does not mean that CCM should 
only support cost-effective interventions in their inception. 
An ex-ante evaluation should be performed before or during 
grant application and the ex-post evaluation routinely 
during the grant implementation.14 This is to ensure that the 
CCM can classify the interventions into categories shown 
in Figure. There are four possible types of interventions 
that are available for HIV, TB, and malaria. Intervention A 
shows good VFM from program commencement and in the 
long-term. Interventions B and C are cost-ineffective in the 
beginning but show improved VFM over time. The difference 
between interventions B and C is that the former can become 
cost-effective over a short period and even perhaps before a 
country’s graduation from GF support. Intervention D, on the 
other hand, is cost-ineffective from the beginning and even 
over time. 
In theory, country governments should fund interventions 
like intervention A without GF support; nevertheless, if there 
is insufficient health budget, then the GF should prioritize 
these types of interventions. It is difficult, however, to 
determine the differences between interventions B, C, and D 
in the beginning phase of their implementation. Investing in 
B, C, and D should be done carefully, ie, implementing those 
as pilots so that they can be easily discontinued if necessary 
before they are scaled up. Accordingly, GF and CCM should 
continuously include cost-effectiveness analysis in their 
monitoring and evaluation mechanisms to determine the 
VFM of these interventions (not just in terms of staying within 
budget, as is currently outlined in their previous funding 
model)15 and thus eventually detect and terminate the high-
cost intervention D. As for interventions B and C, given that 
intervention B is well within the means of the government to 
continue implementation before or at the end of GF support, 
GF should promote prioritization of intervention B and 
countries’ corresponding ownership and responsibility for 
the program. Intervention C, which can eventually become 
cost-effective for the government post-graduation, can be 
considered as an optional investment for countries and a third 
priority.
The VFM can be monitored using both surrogate and final 
outcome. Observing the final outcome at the very beginning 
of program implementation is not often straightforward. For 
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example, for a condom program, it is often not possible to 
monitor the population that uses a condom when having 
sex. As such, there is evidence of higher percentage of the 
population using condoms and the consequent reduction 
in HIV rate. However, at the end of the program, it will be 
necessary to measure the impact on HIV infections per se.
The following recommendations are offered to the GF, 
country governments and their CCMs to ensure the VFM for 
GF investment as well as the smooth transition from the GF 
grant once the countries become more self-sufficient.
Policy Recommendations: To the Global Fund
• Continuing with ending one-size-fits-all governance 
approach for CCM – the GF needs to improve the 
understanding of the country context when working 
with them. With the New Funding Model in 2014-2016 
and 2017-2019, the GF is moving in the right direction in 
increasing country dialogue and working with country 
governments’ national strategies.15,16 However, countries 
may have different health governance arrangements, and 
GF needs to keep certain principles and apply them based 
on the context. One example is the principle behind the 
CCM of having a multi-stakeholder process in designing 
and implementing GF programs. This is already available 
in the Thai context given that the National Health 
Security Office (NHSO) is responsible for treatment for 
HIV, TB, and malaria, and the prevention of HIV and 
TB already have multiple stakeholders on the NHSO 
board. If the GF works with the NHSO board, Thailand 
no longer requires a CCM and the benefit of using the 
existing governance structure is that it ensures country 
ownership, coordination, and integration of health policy, 
effective implementation and long-term sustainability. 
• Making the best use of performance-based financing 
(PBF)17 – to avoid the perception of grants being a 
‘windfall,’ the GF should emphasize PBF payments and 
ensure that the country is aware that if they are not 
performing well and keeping to the target, the grant 
disbursement will be deducted from the next round. 
With the GF’s introduction of the PBF, however, it needs 
to be careful in using the approach properly by avoiding 
punishing grant recipients who are working within 
their means but cannot reach their target, dubbed “poor 
performers,” because of other difficulties, eg, political 
conflict or war, disasters, other difficulties due to poor 
socio-economic status or target population, or factors 
beyond their control. 
• Establishing an HTA[1] mechanism for VFM framework 
– The GF needs to establish mechanisms and tools for 
the GF itself that will help CCM in countries to recognize 
whether the interventions submitted in the concept note 
or grant application are of category A, B, C, or D through 
ex-ante assessment, and be used for ex-post M&E of VFM 
of the GF program. In doing this, the GF may need to 
develop a technical manual, such as a reference case for 
economic evaluation and some standards of evidence to 
guide critical appraisal,18 and teams to assist countries 
for VFM assessments. The GF needs to compile data and 
information from grant applications and M&E processes 
that can in the future be used to guide GF and non-GF 
countries about the value of investment in HIV, TB and 
malaria interventions. In this case, GF or its assigned 
partner could act as an archivist and databank. 
•	 Incorporating social and ethical dimensions in HTA for 
GF – to ensure the success of ending HIV, TB and malaria, 
the GF and country partners need to understand not only 
the health and economic impact of their investment but 
also the impact on equity of access to the GF programs. 
Understanding the social determinants of health on HIV, 
TB and malaria as well as their impact on programs 
targeting these diseases will be crucial to ensure that 
the most difficult-to-reach and at-risk populations 
can benefit from the program. As with the case in GF’s 
programs in Thailand, ending these diseases mean that 
even minority and outreach populations must be able to 
access these programs, and not just the majority of the 
affected population.19,20 Methods such as extended cost-
effectiveness analysis or distributional cost-effectiveness 
analysis exist which can and have been applied to depict 
the distributional impact of allocation decisions and to 
help policy-makers make more equitable decisions.21,22
•	 The GF should use HTA for selection of health 
technologies and price negotiation for its central 
procurement, which can then assist other countries 
making procurements outside of the headquarters. 
This process will help drive VFM of the GF and avoid 
controversies in terms of questionable investments. Using 
VFM evidence for procurement of health technologies 
Figure. VFM of Possible Global Fund Programs/Interventions. Abbreviation: VFM, value-for-money.
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has advantages over price negotiations without using 
VFM evidence, which is the current practice in GF, due 
to its comparative advantage of bulk purchasing. Using 
VFM evidence for pricing means incentivizing industry 
to deliver good value (quite distinct from cheap or 
unprofitable) innovation. This also helps GF avoid the 
trap of investing in low-cost technologies that may have 
minimal impact or in engaging in a cost minimisation 
exercise, exerting its large purchasing power which 
countries are less able to do after transitioning and which 
may bring about complaints of stifling innovation. 
Our recommendations are in line with donor performance 
agreements such as the UK’s Department for International 
Development (DfID)23 and with global funding conduits’ 
own VFM frameworks and strategies and are increasingly 
informing key performance indicators for such institutions. 
Indeed, the GF’s VFM and sustainability special initiative, often 
together with other stakeholders such as the World Bank, has 
encouraged the use of disease-specific models for optimising 
resource allocation such as in the case of Sudan where the 
HIV model Optima was used to inform the national strategic 
plan for HIV resulting in significant modelled improved 
health outcomes.24 Moreover, the GF Market Shaping Strategy 
makes an even clearer case for adopting cost-effectiveness 
analysis to inform product selection at central and country 
level, the latter through proactively funding in country 
cost-effectiveness analyses for its grantees: “The GF…will 
proactively engage with recipients to share relevant analyses 
and information about likely product costs and comparative 
health technology assessments…the GF Secretariat...will 
connect recipients with these resources to inform country-
driven health technology assessment. Engaging in this 
process can also be an opportunity to build country capacity 
for health technology assessment and how to incorporate this 
into product selection decisions.”25
 
Policy Recommendations: To the Countries 
•	 With support from GF and other international partners, 
the CCM (or equivalent authority) and local technical 
bodies need to develop capacity in using and assessing 
VFM as well as social, institutional, and ethical 
consequences of GF investments in the context of a 
broad HTA[1] framework. The CCM must be able to work 
with local and international technical bodies that are 
supporting CCM and its work to continuously monitor 
and evaluate the VFM of their programs over time to 
classify interventions into A, B, C, or D. CCM has the 
authority to discontinue investments if they are found 
not to be good value for money. Moreover, the CCM and 
local partners need to understand the socio-economic, 
ethnic, and geographical factors that affect the programs’ 
effectiveness and to incorporate these concerns in their 
design and implementation. Using HTA in the decision-
making process can also address these issues. 
•	 GF is appropriately geared to assist countries until they 
can sufficiently support themselves. However, during 
this period, countries should be able to engage with 
the GF work through a process that accounts for their 
existing public health programs and local challenges. 
Interventions funded through the GF should be a good 
value for investment, e.g. interventions A and B in Figure, 
for the country itself. Once the transition begins, the GF 
can re-invest the money saved from programs that are 
now transferred to the government to other important 
and/or targeted programs as well. 
In conclusion, our paper illustrates the potential of aligning 
GF efforts with countries’ priority setting, ensuring that 
vertical programmes are considered alongside those under 
national health insurance schemes, which are broader and 
encompass many areas such as NCDs. It also demonstrates 
the utility of using economic evaluation to guide GF and CCM 
investment and management over time. This mechanism will 
ensure sustainability of cost-effective HIV, TB, and malaria 
interventions beyond the GF program and will ensure aid 
budgets, whilst they are relevant, go much further.26 
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Endnotes
[1]  HTA refers to the systematic evaluation of properties, effects, and/or impacts 
of health technology. It is a multidisciplinary process to evaluate the social, 
economic, organizational, and ethical issues of a health intervention or health 
technology. The main purpose of conducting an assessment is to inform a policy 
decision-making.
Health technology assessment. (n.d.). Retrieved August 18, 2015 from http://
www.citationmachine.net/apa/cite-a-website?new=true. 
[2]  The HITAP is a semi-autonomous technical body under the Ministry of Public 
Health, Thailand, that uses HTA to inform UHC benefits package development 
in Thailand.
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[3] The incremental cost-effectiveness ratios (ICERs) of the program were 
compared between the GF program and the Ministry of Public Health program. 
The ICER measures the cost of one healthy life year, accounting for the total 
program costs. The ceiling threshold is the government’s willingness-to-pay for 
one healthy life year.
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